Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses

Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses →

The CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years.